GLG Partners’s Novartis NVS Stock Holding History

GLG Partners’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-54,704	Closed	-$4.51M	–	503
2015 Q3	$4.51M	Buy	54,704 +2,606	+5%	+$232K	0.12%	191
2015 Q2	$4.59M	Buy	+52,098	New	+$4.78M	0.12%	192

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

GLG Partners's NVS Position: Q4 2015 in Review

GLG Partners sold out of Novartis (NVS) in Q4 2015, closing a stake of 54,704 shares — an estimated $4.51M sold.

GLG Partners first reported a position in NVS in Q2 2015 and held it in 2 quarters. The position peaked at $4.59M in Q2 2015. 926 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

GLG Partners reported no remaining Novartis position as of Q4 2015 after selling out during the quarter.
GLG Partners sold 54,704 Novartis shares in Q4 2015, an estimated $4.51M.
GLG Partners first reported a position in Novartis in Q2 2015 and held it in 2 quarters.
GLG Partners's Novartis position peaked at $4.59M in Q2 2015.
926 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on GLG Partners's 13F filing for Q4 2015, filed 16 Feb 2016.